Video Programs

Real-World Insight: Lenvatinib for RAI-Refractory DTC

ByAndrew G. Gianoukakis, MD

September 25th 2020

Lenvatinib Data for RAI-Refractory DTC

ByAndrew G. Gianoukakis, MD

September 25th 2020

Systemic Therapy for RAI-Refractory DTC

ByAndrew G. Gianoukakis, MD

September 25th 2020

Recommendations for Treating Patients With DTC

ByAndrew G. Gianoukakis, MD

September 25th 2020

Case Impressions: A 73-Year-Old Woman With DTC

ByAndrew G. Gianoukakis, MD

September 25th 2020

A 73-Year-Old Woman With Differentiated Thyroid Cancer

ByAndrew G. Gianoukakis, MD

September 25th 2020

Andrew G. Gianoukakis, MD, of Harbor-UCLA Medical Center, describes the rationale for treating a patient with RAI-refractory differentiated thyroid cancer with systemic therapy.